2,2,2-trifluoroacetimidic acid methyl ester | 815-07-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 甲亚胺酸及其衍生物
• 英文名称: 2,2,2-trifluoroacetimidic acid methyl ester
• 英文别名: iminotrifluoroacetic acid methylester；methyl trifluoroacetimidate；2,2,2-trifluoro-acetimidic acid methyl ester；2,2,2-Trifluor-essigsaeure-imido-methylester；Iminotrifluoressigsaeure-methylester；Trifluoressigsaeure-imid-methylester；Methyl 2,2,2-trifluoroethanimidate
• CAS: 815-07-6
• 化学式: C₃H₄F₃NO
• 分子量: 127.066
• InChiKey: JFUXCQSSEVTROW-UHFFFAOYSA-N

物化性质

• 沸点：
  38-38.5 °C(Press: 747 Torr)
• 密度：
  1.2538 g/cm3(Temp: 15 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,2,2-trifluoroacetimidic acid methyl ester 在 肼 作用下， 以 甲醇 为溶剂， 生成 2,2,2-Trifluor-essigsaeure-imido-hydrazid
  参考文献：
  名称：

  Reactions of Perfluoroalkyl Nitriles. VI. Perfluoroacyl Imidates as Intermediates¹

  摘要：

  DOI：

  10.1021/jo01022a032
• 作为产物：
  描述：

  三氟乙腈 、 sodium methylate 以 甲醇 为溶剂， 生成 2,2,2-trifluoroacetimidic acid methyl ester
  参考文献：
  名称：

  Yakubovich,A.Ya. et al., Journal of general chemistry of the USSR, 1966, vol. 36, p. 878 - 885

  摘要：

  DOI：

文献信息

• [EN] MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS<br/>[FR] COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DU PROTÉASOME
  申请人：UNIV CORNELL

  公开号：WO2019075259A1

  公开（公告）日：2019-04-18

  The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R1, R2, R2', R3, R4, R5, R', R", X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R', R", X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

  本发明的化合物由具有以下式I和式(I')的化合物表示，其中取代基R1、R2、R2'、R3、R4、R5、R'、R"、X、Y和Z如本文所定义，取代基R1、R2、R3、R4、R5、R'、R"、X、Y和Z如本文所定义。这些化合物用于治疗细菌感染、寄生虫感染、真菌感染、癌症、免疫紊乱、自身免疫性疾病、神经退行性疾病和紊乱、炎症性疾病，或肌肉萎缩症，或用于为移植的器官或组织提供免疫抑制。
• 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  申请人：Ashton T Wallace

  公开号：US20060074087A1

  公开（公告）日：2006-04-06

  The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及3-氨基-4-苯基丁酸衍生物，它们是二肽基肽酶-IV酶（“DP-IV抑制剂”）的抑制剂，可用于治疗或预防二肽基肽酶-IV酶涉及的疾病，如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗二肽基肽酶-IV酶涉及的这些疾病中使用这些化合物和组合物。
• (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use
  申请人：Janssen Pharmaceutica N.V.

  公开号：US04859684A1

  公开（公告）日：1989-08-22

  Novel (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives, compositions containing the same, and methods of treating androgen dependent disorders in mammals.

  小说(1H-咪唑-1-基甲基)取代苯并咪唑衍生物，含有相同成分的组合物，以及治疗哺乳动物雄激素依赖性疾病的方法。
• 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  申请人：Merck & Co., Inc.

  公开号：US07388019B2

  公开（公告）日：2008-06-17

  The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及3-氨基-4-苯基丁酸衍生物，其是二肽基肽酶IV酶（“DP-IV抑制剂”）的抑制剂，对于涉及二肽基肽酶IV酶的疾病，如糖尿病，尤其是2型糖尿病的治疗或预防有用。本发明还涉及包含这些化合物的制药组合物以及在涉及二肽基肽酶IV酶的这些疾病的预防或治疗中使用这些化合物和组合物。
• Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors
  作者：Hao Zhang、John Ginn、Wenhu Zhan、Yi J. Liu、Annie Leung、Akinori Toita、Rei Okamoto、Tzu-Tshin Wong、Toshihiro Imaeda、Ryoma Hara、Takafumi Yukawa、Mayako Michino、Jeremie Vendome、Thijs Beuming、Kenjiro Sato、Kazuyoshi Aso、Peter T. Meinke、Carl F. Nathan、Laura A. Kirkman、Gang Lin

  DOI：10.1021/acs.jmedchem.2c00611

  日期：2022.7.14

  sub-Saharan Africa. The P. falciparum proteasome is an attractive antimalarial target because its inhibition kills the parasite at multiple stages of its life cycle and restores artemisinin sensitivity in parasites that have become resistant through mutation in Kelch K13. Here, we detail our efforts to develop noncovalent, macrocyclic peptide malaria proteasome inhibitors, guided by structural analysis and

  疟疾每年有超过 2 亿病例和近 50 万人死亡，对全球健康构成威胁，特别是在发展中国家。恶性疟原虫是导致最严重疾病的寄生虫，它已经对所有抗疟药物产生了耐药性。对一线抗疟药物青蒿素和青蒿素联合疗法的耐药性在东南亚普遍存在，并且在撒哈拉以南非洲地区正在出现。恶性疟原虫蛋白酶体是一个有吸引力的抗疟靶点，因为它的抑制作用可以在寄生虫生命周期的多个阶段杀死寄生虫，并恢复因 Kelch K13 突变而产生耐药性的寄生虫对青蒿素的敏感性。在这里，我们详细介绍了我们在结构分析和药代动力学特性的指导下开发非共价大环肽疟疾蛋白酶体抑制剂的努力，从而产生了一种有效的、物种选择性的、代谢稳定的抑制剂。